Hydrogel bio-ink material based on giant salamander skin secretions

Through hydrogel materials based on salamander skin secretions, the biocompatibility and osteogenesis induction of existing bone repair materials are solved, and efficient integration and repair of bone tissue is achieved, suitable for bone defect repair and 3D printing of bioinks .

CN118976157APending Publication Date: 2024-11-19STOMATOLOGICAL HOSPITAL OF CHONGQING MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310522226.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-10
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing bone repair materials have problems such as biocompatibility, immune rejection, risk of spreading disease and decreased biodegradability, and cannot effectively promote the integration of bone tissue and osteogenesis induction.

Method used

Using hydrogel materials based on salamander skin secretions, the mixture of GelMA and salamander skin secretions hydrolysate, cell suspension, sodium persulfate and Ru solution was prepared with osteogenesis-induced differentiation and good mechanics. Performance hydrogel material for bone repair and 3D printing of bioinks.

Benefits of technology

It realizes efficient integration of hydrogel materials and bone tissue, has good biocompatibility and antibacterial properties, can load osteoblasts, promote the repair of bone defects, and realizes pre-crosslinking at low temperatures, improving bioprinting shear thinning properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976157A_ABST
    Figure CN118976157A_ABST
Patent Text Reader

Abstract

The invention relates to the field of bio-ink, in particular to a hydrogel bio-ink material based on giant salamander skin secretions as well as a preparation method and application of the hydrogel bio-ink material. The hydrogel bio-ink material prepared by the invention can be applied in situ and accurately transferred in a specific amount, and the integration of the hydrogel bio-ink material and bone tissues is efficiently and quickly realized through a specific photooxidation-reduction reaction.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological ink, and in particular to a hydrogel biological ink material based on skin secretions of a salamander, a preparation method and uses thereof. Background Art

[0002] Bone tissue is a highly differentiated connective tissue with a hierarchical structure from microscopic to macroscopic. Bones provide both stability and protection to the organism. Therefore, bone defects may lead to serious health problems.

[0003] Bone defects may be caused by different factors, such as trauma, pathological diseases or surgical intervention. Bone repair materials should be able to repair bone tissue and provide biological and / or mechanical properties to the bone defect. Among the currently known natural bone repair materials, autologous bone is taken from the patient himself and has good biocompatibility, but due to the limitation of bone mass, it will also cause additional blood loss and trauma to the patient. Allogeneic decalcified bone is taken from donated human tissue and has good osteoinductivity and osteoconductivity, but the source is small and the price is high. Xenogeneic bone is taken from animals such as cattle and pigs. It has a wide range of sources and has good osteoconductivity, but there is a risk of causing immune rejection and spreading diseases, and high-temperature calcination and other treatment methods may also lead to a decrease in biodegradability. Currently known artificial bone repair materials include metal materials and non-metallic materials. Metal materials mainly include porous titanium and titanium alloys, stainless steel, etc., which are widely available, low-priced, and high-strength, but cannot form bone integration and have poor plasticity. Non-metallic materials are widely available (including various bioceramics, polymer materials, composite materials, etc.), have good biocompatibility, low price, and low strength, but some materials are not suitable for new bone growth. Summary of the invention

[0004] In a first aspect, the present invention provides a method for preparing a hydrogel material, characterized in that the method comprises:

[0005] S1: mixing GelMA and cell culture medium evenly to obtain a first GelMA solution;

[0006] S2: uniformly mixing the first GelMA solution and the hydrolyzate of skin secretions of Silurus davidianus to obtain a second GelMA solution;

[0007] S3, mixing the second GelMA solution and the cell suspension evenly to obtain a third GelMA solution, wherein the cells include osteoblasts;

[0008] S4: mixing the third GelMA solution with the sodium persulfate solution and the Ru solution to obtain a fourth GelMA solution;

[0009] S5: protecting the fourth GelMA solution from light and performing photo-crosslinking to obtain the hydrogel material.

[0010] In some embodiments, the volume ratio of the first GelMA solution to the hydrolyzed salamander skin secretions is 1:1.

[0011] In some embodiments, the concentration of the hydrolyzate of skin secretions of D. caninus is 40 mg / mL-80 mg / mL.

[0012] In some embodiments, the concentration of the hydrolyzate of skin secretions of Microhylidis fischeri is 47 mg / mL-73 mg / mL.

[0013] In some embodiments, the cell culture medium comprises αMEM medium.

[0014] In some embodiments, the concentration of the GelMA in the second GelMA solution comprises 4%-7%.

[0015] In some embodiments, the concentration of the GelMA in the second GelMA solution comprises 6%.

[0016] In some embodiments, a volume ratio of the sodium persulfate solution to the second GelMA solution comprises 1:50, and a volume ratio of the Ru solution to the second GelMA solution comprises 1:50.

[0017] In some embodiments, the concentration of the sodium persulfate solution comprises 0.748 mg / mL-1.87 mg / mL, and the concentration of the Ru solution comprises 2.38 mg / mL-5.95 mg / mL.

[0018] In some embodiments, the concentration of the sodium persulfate solution comprises 0.748 mg / mL.

[0019] In some embodiments, the concentration of the Ru solution comprises 2.38 mg / mL.

[0020] In some embodiments, the temperature of the dark-proof storage comprises 4°C.

[0021] In some embodiments, the volume ratio of the cell suspension to the second GelMA solution comprises 1:10.

[0022] In some embodiments, the conditions for photocrosslinking include: a wavelength of 400-450 nm, a power of 50 mW / cm 2 Photocrosslinking was performed for 10 s.

[0023] In a second aspect, the present invention also provides a hydrogel material prepared by the above method.

[0024] Pure GelMA does not have osteogenic differentiation induction effect. The present invention adds hydrolyzed liquid of skin secretions of salamander, so that the generated hydrogel material has osteogenic differentiation induction effect, and its mechanical properties increase with the increase of the concentration of hydrolyzed liquid of skin secretions of salamander. Rheological detection shows that the hydrogel material provided by the present invention has the characteristic of shear thinning, which is very beneficial for bioprinting.

[0025] After the hydrolyzate of salamander skin secretions is mixed with the visible light photoredox system of Ru and SPS, pre-crosslinking can be achieved at low temperature (such as 4°C). Under the irradiation of visible light, proteins are cross-linked through dityrosine bonds to form a multi-protein complex, thereby preparing a photosensitive hydrogel scaffold.

[0026] The hydrogel material prepared by the present invention can be applied in situ and accurately delivered in a specific amount, and the integration of the hydrogel material and bone tissue can be achieved efficiently and quickly through a specific photo-oxidation-reduction reaction.

[0027] In addition, the hydrogel material prepared by the present invention also has good biocompatibility, antibacterial properties and the like, and can load osteoblasts to further repair bone defects.

[0028] In a third aspect, the present invention also provides use of the above hydrogel material in preparing bone repair materials.

[0029] In a fourth aspect, the present invention also provides use of the above-mentioned hydrogel material in preparing biological ink for 3D printing. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the prior art descriptions are briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention, and for ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor.

[0031] Figure 1A Schematic diagram of the formation of a hydrogel that can be used as a bio-ink after mixing SSAD hydrolyzate with photosensitizer Ru / SPS under white light;

[0032] Figure 1B Figure 2 is the rheological analysis result of different hydrogel groups;

[0033] Figure 2A The results of promoting the proliferation of BMSCs in different hydrogel groups are shown in Figure 2.

[0034] Figure 2B The results of the scratch test for different hydrogel groups are shown in Figure 2.

[0035] Figure 2C The results of the scratch test for different hydrogel groups are shown in Figure 2.

[0036] Figure 2D The results of Transwell experiments of different hydrogel groups are shown in Figure 2.

[0037] Figure 3A Results of live-dead staining experiments for different hydrogel groups;

[0038] Figure 3B The results of the antibacterial properties of different hydrogel groups are shown in Figure 2.

[0039] Figure 4A The results of alkaline phosphatase (ALP) staining experiments of different hydrogel groups are shown;

[0040] Figure 4B It is the quantitative result diagram of alkaline phosphatase (ALP) staining experiment of different hydrogel groups;

[0041] Figure 4C The results of RUNX2 detection in different hydrogel groups are shown in Figure 2;

[0042] Figure 4D The results of OPN detection in different hydrogel groups are shown in Fig.

[0043] Figure 4E Results of OSX detection in different hydrogel groups;

[0044] Figure 5A The results of the Alizarin Red staining experiment of different hydrogel groups;

[0045] Figure 5B The results of the Alizarin Red staining experiment of different hydrogel groups;

[0046] Fig. 6A Micro-CT three-dimensional reconstruction images of SD rats implanted with skull defects in each experimental group at 4 and 8 weeks after surgery;

[0047] Figure 6B The results of the ratio of bone tissue volume to tissue volume in each experimental group are shown in the figure;

[0048] Figure 6C The results of trabecular separation of each experimental group are shown in Figure 2.

[0049] Fig.6D The results of the number of trabeculae in each experimental group are shown in the figure;

[0050] Fig. 6E The figure shows the average thickness of trabecular bone in each experimental group. DETAILED DESCRIPTION

[0051] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0052] Herein "and / or" includes any and all combinations of one or more of the associated listed items.

[0053] Herein, "plurality" means two or more than two, ie, it includes two, three, four, five, etc.

[0054] It should be noted that, in this article, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, an element defined by the sentence "comprises a ..." does not exclude the existence of other identical elements in the process, method, article or device including the element.

[0055] As used in this specification, the term "about" typically means + / - 5% of the stated value, more typically + / - 4% of the stated value, more typically + / - 3% of the stated value, more typically + / - 2% of the stated value, even more typically + / - 1% of the stated value, and even more typically + / - 0.5% of the stated value.

[0056] In this specification, certain embodiments may be disclosed in a format of being in a certain range. It should be understood that such description of "being in a certain range" is merely for convenience and brevity, and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of the range should be considered to have specifically disclosed all possible sub-ranges and independent numerical values ​​within this range. For example, the description of the range 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within this range, such as 1, 2, 3, 4, 5 and 6. Regardless of the breadth of the range, the above rules apply.

[0057] Example 1: Preparation of the hydrogel bio-ink material of the present invention

[0058] 1.1 Exemplary Preparation Method of SSAD Hydrolyzate :

[0059] S1: mixing a disulfide bond reducing agent and a first solvent to obtain a second solvent.

[0060] A suitable first solvent should contain substantially no ions, such as ultrapure water, deionized water, water for injection, pure water, and the like.

[0061] S2: mixing the freeze-dried powder of skin secretions of Siberian salamander with the second solvent to obtain a first mixed solution.

[0062] In fact, there is no specific limitation on the mixing order of the disulfide bond reducing agent, the first solvent and the freeze-dried powder of skin secretions of the salamander (i.e., the step of obtaining the first mixed solution). For example, the first mixed solution can be obtained by adding and mixing the disulfide bond reducing agent, the first solvent and the freeze-dried powder of skin secretions of the salamander together, or by first mixing the disulfide bond reducing agent with the first solvent and then adding the freeze-dried powder of skin secretions of the salamander thereto, or by first mixing the freeze-dried powder of skin secretions of the salamander with the first solvent and then adding the disulfide bond reducing agent thereto, or by first mixing the disulfide bond reducing agent with the freeze-dried powder of skin secretions of the salamander and then adding the first solvent thereto. The ratio of the disulfide bond reducing agent, the first solvent and the freeze-dried powder of skin secretions of the salamander can be adjusted accordingly according to actual needs, and the present invention does not limit this. As an example, the mass ratio of the lyophilized powder of skin secretions of the salamander to the disulfide bond reducing agent may be 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1 or 3:1. The mass ratio of the first solvent to the lyophilized powder of skin secretions of the salamander may be 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1 or 4:1. The concentration of the second solvent may be about 1%-5% (the specific value may be selected as about 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5%, w / w%) according to actual conditions). The lower limit (minimum value) of the mass ratio of the lyophilized powder of skin secretions of the salamander to the disulfide bond reducing agent may be 3:1. The lower limit (minimum value) of the mass ratio of the first solvent to the lyophilized powder of skin secretions of the salamander may be 4:1.

[0063] In some embodiments, the salamander includes one or more of the genera of Giant Salamander, Cryptobranchus, Stream Salamander, Hynomius, Babirus, Clawed Salamander, Fat Salamander, Pseudohyna, Myna, and Hyperborea. The skin is an important respiratory organ of the salamander, and is distributed with mucus glands and granular glands. The reason why the present invention selects the skin secretions of the Chinese giant salamander is that it can represent the mucus secreted by amphibians such as salamanders when stimulated. Electrical stimulation and skin scraping can promote the secretion of mucus.

[0064] S3: fully hydrolyzing the first mixed solution to obtain a second mixed solution.

[0065] The temperature conditions for the hydrolysis include 0-8°C (preferably 0-4°C). The hydrolysis time is related to factors such as the specific hydrolysis temperature, the concentration of the second solvent, and the concentration of the freeze-dried powder of the skin secretions of the salamander. Within the temperature range of 0-8°C, the higher the temperature, the shorter the hydrolysis time; the higher the concentration of the second solvent, the shorter the hydrolysis time; the higher the concentration of the freeze-dried powder of the skin secretions of the salamander, the longer the hydrolysis time. The hydrolysis time may also be related to the specific type of disulfide bond reducing agent used. Therefore, the hydrolysis time can be adjusted accordingly according to actual needs, and the present invention is not limited to this. Exemplary hydrolysis times include 2-168h, preferably 12-48h. Mixing can be carried out in a mixing manner commonly used in the art, such as oscillation mixing, vortex mixing, etc. Preferably, S3 can be carried out in a low-temperature vacuum reactor, and the vacuum degree of the vacuum reactor is <5kPa.

[0066] S4 centrifuges the second mixed solution and collects the supernatant.

[0067] The specific conditions of centrifugation can be adjusted accordingly according to actual needs, and the present invention does not limit this. Exemplary centrifugation conditions include centrifugation at 4500 rpm for 10 min at 4°C.

[0068] S5: the supernatant is placed in a dialysis bag with a molecular weight cut-off of ≤1000 and fully dialyzed in the first solvent to obtain the hydrolyzate of skin secretions of Siberian salamander. The concentration of the hydrolyzate of skin secretions of Siberian salamander can be 5-7%.

[0069] The temperature condition of the dialysis includes 0-8°C (preferably 0-4°C). Preferably, a dialysis bag with a molecular weight cutoff of 500 or 1000 is used. The dialysis time is actually related to the treatment method during dialysis. For example, the dialysis time can be shortened by increasing the number of times the first solvent in the dialysis bag is replaced. Therefore, the dialysis time can be adjusted accordingly according to actual needs, and the present invention does not limit this.

[0070] Wherein, the disulfide bond reducing agent includes a specific disulfide bond reducing agent. In the present invention, "specific disulfide bond reducing agent" refers to a disulfide bond reducing agent that can reduce the intermolecular disulfide bonds in the protein or polypeptide to be reduced, while keeping the intramolecular disulfide bonds as unreduced as possible. The specific disulfide bond reducing agent includes tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl). Of course, in the preparation method of the skin secretion hydrolyzate of the salamander provided by the present invention, it can also be used in combination with common protein denaturants / organic solvents known in the art, such as vitamin C, acetic acid, hydrochloric acid, β-mercaptoethanol, dithiothreitol, EDTA, urea, ethanol, acetone, guanidine hydrochloride, sodium dodecyl sulfate and sodium hydroxide and proteases (such as pepsin, trypsin, papain and subtilisin).

[0071] Furthermore, the method for preparing the hydrolyzate of skin secretions of Siberian salamander provided by the present invention may further include S6 concentrating the hydrolyzate of skin secretions of Siberian salamander to obtain concentrated hydrolyzate of skin secretions of Siberian salamander. The concentration of the concentrated hydrolyzate of skin secretions of Siberian salamander is ≥10%.

[0072] An exemplary concentration method includes placing the hydrolyzate of skin secretions of Siberian salamander into a concentration centrifuge tube with a molecular weight cut-off of ≤3K and centrifuging the hydrolyzate of skin secretions of Siberian salamander or concentrating the hydrolyzate by evaporation.

[0073] Preferably, any of the above steps is performed under vacuum or inert atmosphere.

[0074] In some embodiments, the preparation method includes: placing the collected fresh skin secretions of giant salamander into a sterilized centrifuge tube, washing and centrifuging 3 times with PBS at 4°C, washing and centrifuging once with 5% acetic acid, and then pre-freezing in a -20°C refrigerator for 4 hours. After freeze-drying in a -80°C low-temperature freeze dryer for 24 hours, crushing to 300 mesh with a frozen ball mill, and storing in a -20°C refrigerator for subsequent experiments. The lyophilized powder of giant salamander skin secretions, vitamin C, tris(2-carboxyethyl)phosphine hydrochloride (TCEP), and distilled water are mixed in a mass ratio of 10:5:5:100 for 24 hours. Centrifuge at 4000rpm for 15 minutes, take the supernatant, and dialyze for 24 hours to obtain SSAD hydrolyzate.

[0075] 1.2 Preparation of hydrogel bio-ink materials

[0076] 1.2.1 Preparation of SSAD+Ru bio-ink

[0077] i) Dissolve Ru (Ruthenium) in ddH 2 O or PBS.

[0078] ii) Dissolve SPS (sodium persulfate) in ddH 2 O or PBS.

[0079] iii) The Ru solution and sodium persulfate solution prepared above were added in an amount of 1 / 50 of the volume of the SSAD hydrolyzate, and mixed thoroughly.

[0080] iv) Photocrosslinking using a wavelength of 400-450 nm (at 50 mW / cm 2 , lasting for more than 3 min) to ensure that the SSAD bio-ink is completely cross-linked.

[0081] 1.2.2 Preparation of SSAD bio-ink containing cells

[0082] a) Weigh 60 mg of GelMA into a 1.5 mL eppendorf tube, pipette 500 uL αMEM medium into the eppendorf tube, and shake in a 60°C metal bath for 10 min.

[0083] b) Add 500uL of SSAD hydrolyzate to the GelMA solution prepared in step a) above, shake and mix, then add 100uL of osteoblast suspension (cell volume is 10 6 / mL). The preliminary experiment of the present invention found that when the volume ratio of GelMA solution to SSAD hydrolyzate was 1:1, the generated hydrogel material had more excellent biological and mechanical properties. In addition, the preliminary experiment of the present invention also verified the formability of different GelMA solution concentration gradients (e.g., 4%, 6%, 7%), and the results showed that when the concentration of GelMA solution was 6%, the generated hydrogel material had better formability.

[0084] c) Pipette 20uL of SPS (0.748mg / mL) and Ru (2.38mg / mL) into the ep tube, blow and mix to form a uniform liquid. Put it into a 1mL light-proof syringe, place it at 4℃ for 30min, extrude it evenly into a strip-shaped filament, and irradiate it with strong white light (for example, with a wavelength of 400-450nm, 50mW / cm 2 The concentration of Ru can range from 0.748 mg / mL to 1.87 mg / mL, and the concentration of SPS can range from 2.38 mg / mL to 5.95 mg / mL.

[0085] Embodiment 2

[0086] like Figure 1A As shown, after the SSAD hydrolyzate is mixed with the photosensitizer Ru / SPS, a hydrogel that can be used as a bio-ink can be formed under white light.

[0087] SSAD hydrolyzate is subjected to vacuum concentration in different time periods, and subsequent grouping is SSAD / Ru-0, SSAD / Ru-0.5 and SSAD / Ru-1. The exemplary method of vacuum concentration is to put SSAD hydrolyzate into vacuum centrifugal concentrator, and continuously evacuate with vacuum pump under centrifugal state, even close to vacuum, make SSAD hydrolyzate vacuum concentration 0.5h and 1h, obtain different concentration hydrolyzate. After measurement, the concentration of SSAD-0 group (or SSAD / Ru-0) SSAD hydrolyzate is 47mg / mL, the concentration of SSAD-0.5 group (or SSAD / Ru-0.5) SSAD hydrolyzate is 57mg / mL, and the concentration of SSAD-1 group (or SSAD / Ru-1) SSAD hydrolyzate is 73mg / mL. It should be understood that the concentration of SSAD hydrolyzate of the present invention can be adjusted according to actual needs, such as dilution, concentration, etc.

[0088] Dynamic rheological analysis was performed using a rheometer: the test was performed at 37°C in oscillation mode, the gap distance was set to 0.5 mm, the SSAD hydrogel was placed on the sample stage, the parameters were adjusted, the frequency was set to 1 Hz, the strain was set to 1%, the storage modulus (G') and the loss modulus (G") were tested over time, and the data were recorded. Rheological data ( Figure 1B , triangles represent G” loss modulus, and squares represent G’ storage modulus) show that the mechanical strength of SSAD bio-ink increases with increasing concentration.

[0089] 4×10 3 BMSCs were seeded in a 96-well plate at a density of 1 / well, and different groups of hydrogel extracts were added. After 1 day and 4 days of culture, the culture medium was aspirated, CCK-8 was added, and the OD value was measured after incubation at 37°C for 1 hour. The results of the CCK-8 experiment for 1 day and 4 days showed that SSAD / Ru extract (the concentration of each group of extracts was 150ul / ml) could promote the proliferation of BMSCs ( Figure 2A ).

[0090] 5×10 5 BMSCs were seeded in a 6-well plate at a density of 1.5 / well. After 24 hours, a straight line was drawn with a 200ul pipette tip. After drawing, the plates were washed with PBS and serum-free culture medium was added. The experimental group was added with hydrogel extract and photographed after 24 hours. The results of the scratch test after 24 hours showed that SSAD / Ru-0 promoted the migration of BMSCs ( Figure 2B , Figure 2C ).

[0091] Add 500ul of 10% FBS culture medium to the lower chamber of the 24-well plate, add hydrogel extract to the experimental group, and then use tweezers to place the Transwell chamber in the 24-well plate. Add 100ul of 5×10 5 / ml cell suspension was placed in the upper chamber of the Transwell and fixed and stained after 24h of culture. No significant difference was observed in the results of the Transwell experiment after 24h ( Figure 2D ).

[0092] BMSCs were plated at 1x10 6 The cells were inoculated at a density of 100 cells / mL on three freeze-dried hydrogels and cultured for 1, 4, and 7 days. Live and dead staining was performed at the corresponding time points. The results showed that the cells in the SSAD / Ru-0 group had the best growth state ( Figure 3A ).

[0093] The bacterial suspension of Escherichia coli and Staphylococcus aureus (1.0×10 5 CFU / mL) were sprayed on the surface of SSAD hydrogels with different concentrations and then transferred to agar medium, placed in an incubator (37°C) for 24 hours, and then taken out to observe the growth of bacteria in each group. The results showed that ( Figure 3B ), SSAD / Ru hydrogels in each group had antibacterial effect upon contact.

[0094] Embodiment 3

[0095] In this example, alkaline phosphatase (ALP) staining experiments were performed with 4×10 4 BMSCs were seeded in a 24-well plate at a density of 1:1 / well. After culturing for 24 hours, different groups of hydrogel extracts were added. After 7 days of osteogenic induction, the cells were fixed and BCIP / NBT (BCIP is 5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt, NBT is tetrazolium chloride nitro blue) working solution was added. The cells were incubated at room temperature in the dark for 30 minutes. After the reaction was terminated, the images were observed and taken.

[0096] The cell seeding density and seeding method of the Alizarin Red staining experiment were the same as those of the ALP staining. After 21 days of osteogenic induction, the cells were fixed, incubated with Alizarin Red staining solution at room temperature for 15 minutes, and observed and photographed after washing with PBS. The cell seeding density and seeding method of the osteogenic differentiation gene expression detection experiment were the same as those of the ALP staining. After 14 days of osteogenic induction, RNA of each group of cells was extracted for qRT-PCR detection.

[0097] The results of alkaline phosphatase (ALP) staining and quantitative detection after 7 days of osteogenic differentiation in each group showed that SSAD / RU-0 and SSAD / RU-0.5 groups had osteogenic effects ( Figure 4A , Figure 4B ) After 14 days of osteogenic differentiation, RUNX2 ( Figure 4C )、OPN( Figure 4D )、OSX mRNA( Figure 4E ) The results of the test showed that the SSAD / RU-0 group had the best bone formation result.

[0098] The alizarin red staining results after osteogenic induction and differentiation for 21 days in each group showed that the SSAD / RU-0 group had the highest calcium nodule content ( Figure 5A , Figure 5B ).

[0099] Example 4

[0100] In the in vivo experiment of this example, a rat cranial defect model was constructed. Circular bone defects with a diameter of 5 mm were constructed on both sides of the skull of 8-week-old healthy male rats. The groups were divided into a blank control group, an SSAD hydrogel group (SSAD / Ru-0), and an SSAD hydrogel cell-loaded group (SSAD / Ru-0 + osteoblasts). Samples were taken at 4 weeks and 8 weeks after surgery, and Micro-CT-related analyses were performed after fixation.

[0101] Fig. 6A Figures 4W and 8W after implantation of the bioprinting ink into the cranial defect of SD rats are Micro-CT three-dimensional reconstruction images. Compared with the blank group, the bone defect area of the SSAD bioprinting ink and the SSAD bioprinting ink mixed cell group was significantly reduced. The Micro-CT results showed that compared with the blank group, both the SSAD hydrogel group and the SSAD hydrogel cell-loaded group had a certain degree of bone formation effect ( Fig. 6A ). Figure 6B Figure 5 is the result chart of the ratio of bone tissue volume to tissue volume. The bone mass in each group increased at the 8W time point compared with the 4W time point, and the bone mass in the blank group < the bone mass in the SSAD group < the bone mass in the SSAD mixed cell group. Figure 6C Figure 6 is the result chart of trabecular bone separation. The trabecular bone separation in each group decreased at the 8W time point compared with the 4W time point, and the trabecular bone separation in the blank group > the trabecular bone separation in the SSAD group > the trabecular bone separation in the SSAD mixed cell group. Fig.6D Figure 7 is the result chart of trabecular bone number. The trabecular bone number in each group increased at the 8W time point compared with the 4W time point, and the trabecular bone number in the blank group < the trabecular bone number in the SSAD group < the trabecular bone number in the SSAD mixed cell group. Fig. 6E Figure 8 is the result chart of the average trabecular bone thickness. The trabecular bone thickness in each group increased at the 8W time point compared with the 4W time point, and the trabecular bone thickness in the blank group < the trabecular bone thickness in the SSAD group < the trabecular bone thickness in the SSAD mixed cell group. The overall results of the quantitative analysis of BV / TV, Tb.Sp, Tb.N, and Tb.Th showed that the hydrogel material provided by the present invention exhibited excellent bone defect repair ability in the cranial defect model ( Figure 6B , Figure 6C , Fig.6D , Fig. 6E ).

[0102] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation methods. The above-mentioned specific implementation methods are merely illustrative and not restrictive. Under the enlightenment of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the purpose of the present invention and the claims, which all fall within the protection of the present invention.

Claims

1. A method for preparing a hydrogel material, It is characterized in that The method comprises: S1: mixing GelMA and cell culture medium evenly to obtain a first GelMA solution; S2: uniformly mixing the first GelMA solution and the hydrolyzed solution of skin secretions of Siberian salamander to obtain a second GelMA solution, wherein the volume ratio of the first GelMA solution to the hydrolyzed solution of skin secretions of Siberian salamander is 1:1; S3, mixing the second GelMA solution and the cell suspension evenly to obtain a third GelMA solution, wherein the cells include osteoblasts; S4: mixing the third GelMA solution with the sodium persulfate solution and the Ru solution to obtain a fourth GelMA solution; S5: protecting the fourth GelMA solution from light and performing photo-crosslinking to obtain the hydrogel material.

2. The method according to claim 1, It is characterized in that The concentration of the GelMA in the second GelMA solution is 4%-7%.

3. The method according to claim 1, It is characterized in that The concentration of the hydrolyzate of skin secretions of the salamander includes 40 mg / mL-80 mg / mL.

4. The method according to claim 1, It is characterized in that The cell culture medium includes αMEM medium.

5. The method according to claim 1, It is characterized in that The volume ratio of the sodium persulfate solution to the second GelMA solution is 1:50, and the volume ratio of the Ru solution to the second GelMA solution is 1:

50.

6. The method according to claim 1, It is characterized in that The concentration of the sodium persulfate solution includes 0.748 mg / mL-1.87 mg / mL, and the concentration of the Ru solution includes 2.38 mg / mL-5.95 mg / mL.

7. The method according to claim 1, It is characterized in that The temperature for keeping away from light includes 4°C.

8. The hydrogel material prepared by the method according to claims 1-7.

9. Use of the hydrogel material according to claim 8 in preparing bone repair materials.

10. Use of the hydrogel material according to claim 8 in preparing biological ink for 3D printing.